Japan-based Eisai will market its breast cancer treatment Halaven (eribulin) in selected countries within the Middle East region through a new partnership between Eisai EMEA and NewBridge Pharmaceuticals.
Eribulin is indicated for
Dubai-based NewBridge Pharmaceuticals has signed an exclusive licensing and distribution agreement with Orexo AB to market Abstral, a key product for treatment of breakthrough cancer pain, in the Middle East and Africa region.
The Dubai-based NewBridge Pharmaceuticals has completed its $12 million Series B financing, bringing the total amount raised to $16 million.
NewBridge also announced today the appointment of Joseph W Henein as its president and chief execu